
## Luis José AldÃ;miz-EchevarrÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7509940/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease. International Journal of Molecular Sciences, 2012, 13, 11288-11311.	4.1	70
2	An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 439-448.	3.3	44
3	Risk factors for developing mineral bone disease in phenylketonuric patients. Molecular Genetics and Metabolism, 2013, 108, 149-154.	1.1	38
4	Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases. Orphanet Journal of Rare Diseases, 2014, 9, 187.	2.7	34
5	Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. Patient Preference and Adherence, 2017, Volume 11, 1489-1496.	1.8	28
6	Lipid profile status and other related factors in patients with Hyperphenylalaninaemia. Orphanet Journal of Rare Diseases, 2016, 11, 123.	2.7	26
7	Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: Impact on growth in PKU. Molecular Genetics and Metabolism, 2013, 109, 331-338.	1.1	24
8	Molecular epidemiology and genotype–phenotype correlation in phenylketonuria patients from South Spain. Journal of Human Genetics, 2013, 58, 279-284.	2.3	20
9	Quantification of Arginine and its Methylated Derivatives in Healthy Children by Liquid Chromatography-Tandem Mass Spectrometry. Journal of Chromatographic Science, 2015, 53, 787-792.	1.4	18
10	New evidence for assessing tetrahydrobiopterin (BH4) responsiveness. Metabolism: Clinical and Experimental, 2012, 61, 1809-1816.	3.4	14
11	Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats. Journal of Physiology and Biochemistry, 2016, 72, 555-566.	3.0	14
12	6R-tetrahydrobiopterin treated PKU patients below 4years of age: Physical outcomes, nutrition and genotype. Molecular Genetics and Metabolism, 2015, 115, 10-16.	1.1	10
13	New <i><scp>CTSA</scp></i> mutation in early infantile galactosialidosis. Pediatrics International, 2018, 60, 761-762.	0.5	5
14	Postauthorization safety study of betaine anhydrous. Journal of Inherited Metabolic Disease, 2022, 45, 719-733.	3.6	5
15	New variants in Spanish Niemann–Pick type c disease patients. Molecular Biology Reports, 2020, 47, 2085-2095.	2.3	4
16	Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176, 112798.	2.8	3
17	Asymmetric dimethylarginine as a potential biomarker for management and follow-up of phenylketonuria. European Journal of Pediatrics, 2019, 178, 903-911.	2.7	2